Cogent Biosciences Income Statement (2017-2026) | COGT

Income Statement Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity) (Quarter)
39.85M43.81M45.82M49.39M69.86M69.89M70.95M85.33M86.12M86.12M95.61M109.34M110.46M110.46M113.86M113.93M139.83M128.90M170.77M173.52M
Revenue & cost
Revenue (Quarter)
Operating items
Research & Development (Quarter)
14.80M20.51M25.47M29.48M29.94M36.74M36.04M38.87M50.13M48.72M52.70M54.29M63.61M62.05M63.03M62.20M68.99M75.56M75.36M70.81M
Selling, General & Administrative (Quarter)
5.02M5.13M5.95M6.38M6.88M7.00M7.20M8.21M9.45M9.51M9.70M10.09M11.80M11.69M11.90M13.38M14.37M23.93M28.24M31.83M
Other Operating Expenses (Quarter)
Operating Expenses (Quarter)
19.82M25.64M31.42M35.85M36.82M43.74M43.24M47.09M59.58M58.23M62.40M64.39M75.41M73.73M74.93M75.58M83.36M99.49M103.61M102.64M
Operating Income (Quarter)
-19.82M-25.64M-31.42M-35.85M-36.82M-43.74M-43.24M-47.09M-59.58M-58.23M-62.40M-64.39M-75.41M-73.73M-74.93M-75.58M-83.36M-99.49M-103.61M-102.64M
EBIT (Quarter)
-19.82M-25.64M-31.42M-35.85M-36.82M-43.74M-43.24M-47.09M-59.58M-58.23M-62.40M-64.39M-75.41M-73.73M-74.93M-75.58M-83.36M-99.49M-103.61M-102.64M
Non-operating items
Interest & Investment Income (Quarter)
0.12M-0.36M0.11M0.27M1.50M4.15M0.12M-0.11M-0.07M0.42M-0.28M-0.15M1.09M17.44M2.95M-0.15M3.89M-9.30M-0.77M7.46M
Other Non Operating Income (Quarter)
0.62M0.62M0.68M0.66M0.26M0.66M0.68M0.27M-0.01M-0.00M0.04M0.00M1.95M-0.01M-0.01M-0.00M-0.01M-0.14M-0.01M
Non Operating Income (Quarter)
0.73M0.73M0.78M0.93M1.76M4.13M4.65M3.01M4.20M3.86M4.06M5.44M4.78M5.81M2.95M2.05M2.42M-3.00M6.25M6.23M
Net income details
EBT (Quarter)
-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-59.96M-71.98M-76.05M-85.22M-110.06M-111.20M-101.72M
Profit After Tax (Quarter)
-19.08M-24.91M-30.63M-34.93M-35.23M-39.45M-8.53M-45.31M-58.35M-58.95M-70.63M-3.44M-72.27M-73.53M-80.93M-102.50M-97.35M-96.76M
Income from Continuing Operations (Quarter)
-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-59.96M-71.98M-76.05M-85.22M-110.06M-111.20M-101.72M
Consolidated Net Income (Quarter)
-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-59.96M-71.98M-76.05M-85.22M-110.06M-111.20M-101.72M
Income towards Parent Company (Quarter)
-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-59.96M-71.98M-76.05M-85.22M-110.06M-111.20M-101.72M
Preferred Dividend Payments (Quarter)
Net Income towards Common Stockholders (Quarter)
-20.17M-26.82M-35.91M-74.62M-48.03M-39.98M-43.12M-47.30M-59.83M-58.99M-62.75M-64.73M-74.33M-59.96M-71.98M-76.05M-85.22M-110.06M-111.20M-101.72M
Additional items
EPS (Basic) (Quarter)
-0.51-0.69-0.80-1.51-0.69-0.68-0.61-0.63-0.69-0.74-0.66-0.65-0.67-0.58-0.64-0.66-0.62-0.85-0.69-0.59
EPS (Diluted) (Quarter)
-0.51-0.69-0.80-1.51-0.69-0.68-0.61-0.63-0.69-0.74-0.66-0.65-0.67-0.58-0.64-0.66-0.62-0.85-0.69-0.59
Shares Outstanding (Quarter)
39.85M38.73M45.11M49.39M69.58M58.74M70.73M74.75M86.17M79.66M94.80M99.24M110.17M103.86M113.31M114.47M137.55M128.90M162.19M171.01M
Shares Outstanding (Diluted) (Quarter)
39.85M38.73M45.11M49.39M69.58M58.74M70.73M74.75M86.17M79.66M94.80M99.24M110.17M103.86M113.31M114.47M137.55M128.90M162.19M171.01M
EBITDA (Quarter)
-19.82M-25.64M-31.42M-35.85M-36.82M-43.74M-43.24M-47.09M-59.58M-58.23M-62.40M-64.39M-75.41M-73.73M-74.93M-75.58M-83.36M-99.49M-103.61M-102.64M
Interest Expenses (Quarter)
0.46M0.82M4.60M39.04M12.71M0.39M0.10M0.17M1.18M0.06M0.19M3.66M0.00M0.31M5.75M1.26M6.83M6.54M